Conference abstract · 23 Apr 2018
Conference abstractPublished 2015
Myocardial regeneration via cellular reprogramming
Baylor College of Medicine, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Congestive heart failure (CHF) is typically occurring as a result of myocardial infarction, and is the leading cause of cardiac mortality in the West afflicting over 5 million individuals and costing over $10 billion in medical care in the US alone. Cardiac stem cell therapy which theoretically repopulates otherwise permanently scarred myocardium with contractile cells has offered some promise in clinical trials. This strategy remains inherently constrained, however, by the hurdles of achieving adequate exogenous implant survival and integration into host myocardium. Potential risks of induced pluripotent stem (iPS) cell tumorigencity and immunogenicity may likewise limit these as stem cell implants. The recent discovery that “induced cardiomyocyte” (iCM) cells could be generated directly from somatic cells for example using cocktails of transcription factors such as GATA4, MEF2c and TBX5 offers the remarkable new possibility of bypassing stem cell staging completely in the generation of autologous cardiomyocytes from cardiac fibroblasts.“Cellular reprogramming” likewise presents the intriguing possibility of converting scar fibroblasts in situ into functional iCMs, obviating entirely the challenges of exogenous cell implantation into a host myocardium. By converting scar directly back into functional myocardium, this transformational advance would eliminate the challenges of exogenous stem cell delivery that have slowed this field since its inception. While new evidence suggests that human cells may be more resistant to reprogramming than those transdifferentiated in small animal models, a number of methodologies are being developed to enable reprogramming even of human cells. Taken together, these new studies suggest an entirely new paradigm in CHF treatment that could potentially replace conventional therapies for end stage heart disease include transplant and artificial heart implant strategies.
Subjects
EngineeringAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 23 Aug 2017
Sonic hedgehog signaling promotes Müller glia reprogramming in regenerating zebra fish/mouse retina: Towards curing retinal diseases
Opinion · 30 Mar 2026
Genetic Engineering and the Transformation of Regenerative Medicine Through Cellular Reprogramming
Conference abstract · 12 Jul 2018
Overview of studies on bone marrow concentrates for myocardial tissue regeneration, with emphasis on new preparation technology addressing cell composition, erythrocyte contamination, and plasma free hemoglobin
Research article · 2017
pH-Sensitive Chitosan Hydrogel with Instant Gelation for Myocardial Regeneration
More from this journal
The newest in Journal of Regenerative Medicine.
Research article · 11 Jun 2026
Collagen Hydrolysates, from Beauty Supplements to Supporting Wound Healing: How Solid is the Rationale? An Overview and Insights for Regenerative Medicine Practitioners
Research article · 8 Aug 2025
Human Umbilical Cord-Derived Mesenchymal Stem Cells in Combination with Small Extracellular Vesicles Prevent the Development of Fibrosis and Cirrhosis and Improve Survival in Wistar Rats Receiving CCl₄
Opinion · 20 Feb 2025
CAR-T Cell Therapy: Expanding Applications beyond Hematologic Malignancies
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Regenerative Medicine
- SubjectEngineering
- BylineArticles whose byline prints “Todd K Rosengart”

